HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Resistance to APC and SHBG levels during use of a four-phasic oral contraceptive containing dienogest and estradiol valerate: a randomized controlled trial.

AbstractBACKGROUND:
The use of combined oral contraceptives is associated with a 3- to 6-fold increased risk of venous thrombosis. This increased risk depends on the estrogen dose as well as the progestogen type of combined oral contraceptives. Thrombin generation-based activated protein C resistance (APC resistance) and sex hormone-binding globulin (SHBG) levels predict the thrombotic risk of a combined hormonal contraceptive. Recently, a four-phasic oral contraceptive containing dienogest (DNG) and estradiol valerate (E2V) has been marketed. The aim of this study was to evaluate the thrombotic risk of the DNG/E2V oral contraceptive by comparing APC resistance by measuring normalized APC sensitivity ratios (nAPCsr) and SHBG levels in users of oral contraceptives containing dienogest and estradiol valerate (DNG/E2V) and oral contraceptives containing levonorgestrel and ethinyl estradiol (LNG/EE).
METHODS:
We conducted a single-center, randomized, open label, parallel-group study in 74 women using DNG/E2V or LNG/EE, and measured nAPCsr and SHBG levels in every phase of the regimen of DNG/E2V.
RESULTS:
During the pill cycle SHBG levels did not differ between DNG/E2V users and LNG/EE users. nAPCsr levels were overall slightly lower in DNG/E2V users than in LNG/EE users, mean difference -0.44 (95% CI, -1.04 to 0.17) for day 2, -0.20 (95% CI, -0.76 to 0.37) for day 7, -0.27 (95% CI, -0.81 to 0.28) for day 24 and -0.34 (95% CI, -0.91 to 0.24) for day 26.
CONCLUSION:
No statistical significant differences in nAPCsr and SHBG levels were found between users of the oral contraceptive containing DNG/E2V and LNG/EE, suggesting a comparable thrombotic risk.
AuthorsM Raps, F Rosendaal, B Ballieux, J Rosing, S Thomassen, F Helmerhorst, H van Vliet
JournalJournal of thrombosis and haemostasis : JTH (J Thromb Haemost) Vol. 11 Issue 5 Pg. 855-61 (May 2013) ISSN: 1538-7836 [Electronic] England
PMID23410231 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2013 International Society on Thrombosis and Haemostasis.
Chemical References
  • Contraceptives, Oral, Combined
  • Sex Hormone-Binding Globulin
  • dienogest
  • Estradiol
  • Nandrolone
  • estradiol valerate
Topics
  • Activated Protein C Resistance (blood)
  • Adolescent
  • Adult
  • Contraceptives, Oral, Combined (administration & dosage)
  • Estradiol (administration & dosage, analogs & derivatives)
  • Female
  • Humans
  • Nandrolone (administration & dosage, analogs & derivatives)
  • Sex Hormone-Binding Globulin (metabolism)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: